By Katherine Hamilton
Shares of Prothena climbed Thursday after the company said a trial of its Parkinson's treatment suggests potential clinical benefits in the early stages of the disease, even though it missed its primary endpoint.
The stock was up 37.5% to $16.41 in recent trading and. It has fallen about 55% this year.
The study, conducted by Roche, investigated prasinezumab in almost 600 people with early-stage Parkinson's disease.
The treatment showed potential clinical effect, including a delay in motor progression, as well as consistent positive trends across multiple secondary and exploratory endpoints. There were no new safety issues.
The results will inform further clinical development of prasinezumab as a potential disease-modifying treatment for Parkinson's patients, the biotechnology company said.
Roche is evaluating the data and will work with health authorities to determine next steps, Prothena said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 19, 2024 15:21 ET (20:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。